EZH2 and non-Hodgkin lymphoma: Studies on intervertebral disc tissue have identified epigenetic markers that act as target biomarkers, such as ALKBH, which can promote cellular senescence and contribute to intervertebral disc degeneration [34], or that appear to be responsive to pharmacological modulation, such as EZH2, already used as a target in non-Hodgkin’s lymphoma therapy (Tazemetostat).